By focusing on investigators the MErCuRIC project will develop a network of experienced clinicians. They will spearhead changes in current clinical practices embedding best practice from across Europe. MErCuRIC will improve the survival rates of metastatic colorectal cancer patients.
We are targeting two groups that have a particularly poor prognosis in colorectal cancer. This is the first time that a combinatorial approach has been adopted targeting MET and MEK inhibition simultaneously. By leveraging existing drugs the potential for adverse pharmacological problems is minimized.